Education
About Us
Working with TipRanks
Follow Us
Biodexa Pharmaceuticals (BDRX)
NASDAQ:BDRX
BDRX Stock Chart & Stats
$3.64
$0.02(0.46%)
At close: 4:00 PM EST
$3.64
$0.02(0.46%)
Day’s Range― - ―
52-Week Range$3.58 - $92.00
Previous CloseN/A
Volume6.04K
Average Volume (3M)260.97K
Market Cap
$2.26M
Enterprise Value-$3.53M
Total Cash (Recent Filing)$4.04M
Total Debt (Recent Filing)$501.00K
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Apr 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding619,523
10 Day Avg. Volume685,915
30 Day Avg. Volume260,967
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.41
Price to Sales (P/S)0.00
P/FCF Ratio-1.54
Enterprise Value/Market Cap-1.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.72
Enterprise Value/Ebitda0.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biodexa Pharmaceuticals News
BDRX FAQ
What was Biodexa Pharmaceuticals’s price range in the past 12 months?
Biodexa Pharmaceuticals lowest stock price was $3.58 and its highest was $92.00 in the past 12 months.
What is Biodexa Pharmaceuticals’s market cap?
Biodexa Pharmaceuticals’s market cap is $2.26M.
When is Biodexa Pharmaceuticals’s upcoming earnings report date?
Biodexa Pharmaceuticals’s upcoming earnings report date is Apr 24, 2026 which is in 124 days.
How were Biodexa Pharmaceuticals’s earnings last quarter?
Biodexa Pharmaceuticals released its earnings results on Sep 12, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.004 by $0.004.
Is Biodexa Pharmaceuticals overvalued?
According to Wall Street analysts Biodexa Pharmaceuticals’s price is currently Overvalued.
Does Biodexa Pharmaceuticals pay dividends?
Biodexa Pharmaceuticals does not currently pay dividends.
What is Biodexa Pharmaceuticals’s EPS estimate?
Biodexa Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biodexa Pharmaceuticals have?
Biodexa Pharmaceuticals has 619,523 shares outstanding.
What happened to Biodexa Pharmaceuticals’s price movement after its last earnings report?
Biodexa Pharmaceuticals reported an EPS of $0 in its last earnings report, beating expectations of -$0.004. Following the earnings report the stock price went up 1.518%.
Which hedge fund is a major shareholder of Biodexa Pharmaceuticals?
Currently, no hedge funds are holding shares in BDRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biodexa Pharmaceuticals
Biodexa Pharmaceuticals (BDRX) is a biotechnology company focused on the development and commercialization of innovative therapeutic solutions. Operating primarily in the pharmaceutical sector, the company specializes in the research and development of drug delivery systems and proprietary drug formulations designed to enhance patient outcomes. Its core products include advanced pharmaceutical compounds and delivery technologies that address unmet medical needs in various therapeutic areas.
Technical Analysis
Salarius Pharmaceuticals
―
Indaptus Therapeutics
―
InMed Pharmaceuticals
―
Enveric Biosciences
―
CNS Pharmaceuticals
―
Ownership Overview
1.87%
Insiders
― Other Institutional Investors
98.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---